Arbutus Biopharma
ABUS
77 hedge funds and large institutions have $616M invested in Arbutus Biopharma in 2015 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 18 closing their positions.
841% more capital invested
Capital invested by funds: $65.5M → $616M (+$550M)
173% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $3.78M
156% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 18
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
57% more funds holding
Funds holding: 49 → 77 (+28)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
+$328M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$55.6M |
| 3 |
AWG
Alpha Wave Global
New York
|
+$45.5M |
| 4 |
BRC
Blue Ridge Capital
New York
|
+$34.8M |
| 5 |
D.E. Shaw & Co
New York
|
+$33.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$6.22M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.95M |
| 3 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$1.89M |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$1.11M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.05M |
ABUS Hedge Fund Activity: Q1 2015 in Review
77 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2015, worth a combined $616M — up 841% from $65.5M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ABUS positions and 18 closed out — a net gain of 28 holders — while 17 added to existing stakes and 8 trimmed.
The largest buyer was QVT Financial, opening a new position worth an estimated $328M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.22M.
- 77 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2015, up from 49 in Q4 2014.
- Funds reported $616M of Arbutus Biopharma stock for Q1 2015, up 841% quarter-over-quarter.
- 46 funds opened new Arbutus Biopharma positions in Q1 2015 and 18 closed out, a net change of +28 holders.
- The largest Arbutus Biopharma buyer in Q1 2015 was QVT Financial, an estimated $328M added.
- The largest Arbutus Biopharma seller in Q1 2015 was Baker Bros. Advisors, an estimated $6.22M sold.
Based on aggregated 13F filings for Q1 2015.